12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Qsymia phentermine/topiramate regulatory update

As expected, EMA's CHMP issued a negative opinion against approval of an MAA for obesity drug Qsiva phentermine/topiramate from Vivus. The committee expressed concerns over the potential cardiovascular and CNS effects associated with long-term use, Qsiva's teratogenic potential and its use by patients for...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >